2-(2-(((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)carbamoyl)-2,3-dihydro-1H-inden-2-yl)acetic acid

ID: ALA4762834

Chembl Id: CHEMBL4762834

PubChem CID: 135338696

Max Phase: Preclinical

Molecular Formula: C21H21N3O3

Molecular Weight: 363.42

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Cn1c(CNC(=O)C2(CC(=O)O)Cc3ccccc3C2)nc2ccccc21

Standard InChI:  InChI=1S/C21H21N3O3/c1-24-17-9-5-4-8-16(17)23-18(24)13-22-20(27)21(12-19(25)26)10-14-6-2-3-7-15(14)11-21/h2-9H,10-13H2,1H3,(H,22,27)(H,25,26)

Standard InChI Key:  DSUHCTIURNZXIX-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4762834

    ---

Associated Targets(non-human)

ACE Angiotensin-converting enzyme (2863 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 363.42Molecular Weight (Monoisotopic): 363.1583AlogP: 2.45#Rotatable Bonds: 5
Polar Surface Area: 84.22Molecular Species: ACIDHBA: 4HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.13CX Basic pKa: 4.82CX LogP: 1.76CX LogD: -0.35
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.73Np Likeness Score: -0.91

References

1. Leiris S,Davies DT,Sprynski N,Castandet J,Beyria L,Bodnarchuk MS,Sutton JM,Mullins TMG,Jones MW,Forrest AK,Pallin TD,Karunakar P,Martha SK,Parusharamulu B,Ramula R,Kotha V,Pottabathini N,Pothukanuri S,Lemonnier M,Everett M.  (2021)  Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors.,  12  (2.0): [PMID:33603968] [10.1021/acsmedchemlett.0c00554]

Source